Back to top

gene-editing: Archive

Zacks Equity Research

Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates

SRPT posts a wider Q4 loss as Elevidys sales tumble, but revenues top estimates and 2026 guidance outlines a cautious recovery path.

RHHBYPositive Net Change SRPTNegative Net Change ARWRNegative Net Change

Ekta Bagri

Genomics Stocks That Deserve a Place in Your Portfolio in 2026

Genomics and synthetic biology are reshaping healthcare, as rapid DNA sequencing advances power personalized medicine and strong market growth.

ILMNPositive Net Change BEAMNegative Net Change PACBNegative Net Change CRSPNegative Net Change SANANegative Net Change CRBUNegative Net Change